Special Issue

Biomaterials for Drug Delivery in Radiotherapy

Message from the Guest Editors

With the increasing use of biomaterials in conjunction with radiation therapy for various diseases, research in this field is gaining momentum. Biomaterials have the potential to enhance imaging technologies for diagnostics and improve drug delivery by directly (e.g., metallic nanoparticles) or indirectly (e.g., immunoadjuvants or therapeutic agents) enhancing radiation therapy. Additionally, biomaterials can help protect healthy tissue from radiation damage, making them a crucial component in modern treatment strategies. These materials also play a vital role in controlled drug release, delivering therapeutic agents precisely to targeted areas. This not only improves radiotherapy effectiveness but also minimizes adverse effects on surrounding healthy tissue. We welcome original research and reviews on:

- Polymer-based biomaterials/hydrogels
- Lipid-based biomaterials
- Organic/inorganic biomaterials, including immunoadjuvants

These materials, whether natural or synthetic, can serve as targeted drug carriers, optimizing therapeutic outcomes with radiation therapy. We look forward to your contributions.

Guest Editors

Dr. Sayeda Yasmin-Karim

Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA

Dr. Fleury Augustin Nsole Biteghe

The Department of Chemistry and Chemical Biology, Northeastern University (Boston) the College of Science, 360 Huntington Avenue, Boston, MA 02115, USA

Deadline for manuscript submissions

closed (30 September 2025)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/233786

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

